Infinity Pharmaceuticals Inc (INFI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Infinity Pharmaceuticals Inc (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10101
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company that discovers and develops small molecule therapeutics for the treatment of cancer. The company’s pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. It is evaluating IPI-549 as a monotherapy in Phase 2 for a solid tumor. Infinity Pharmaceuticals is also investigating IPI-549 in Phase 1 for solid tumors, and in Phase 1B for non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), mesothelioma, adrenocortical carcinoma, and myeloid-derived suppressor cells (MDSC). Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Infinity Pharmaceuticals Inc (INFI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11
Partnerships 12
Bristol-Myers Squibb and Infinity Pharma Enter into Collaboration Agreement 12
Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 13
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 14
Pharm-Olam International Enters into Agreement with Infinity Pharma 15
Lead Discovery Center Partners with Infinity Pharma 16
Licensing Agreements 17
PellePharm Enters into Licensing Agreement with Infinity Pharma 17
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 18
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 20
Equity Offering 21
Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 21
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 23
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 24
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 26
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 27
Infinity Pharmaceuticals Inc – Key Competitors 29
Infinity Pharmaceuticals Inc – Key Employees 30
Infinity Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Strategy And Business Planning 32
Nov 07, 2018: Bristol-Myers and Infinity partner for trial of opdivo and IPI-549 32
Financial Announcements 33
Nov 05, 2018: Infinity Pharmaceuticals provides company update and third quarter 2018 financial results 33
Aug 07, 2018: Infinity Pharmaceuticals provides company update and second quarter 2018 financial results 35
May 08, 2018: Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results 36
Nov 07, 2017: Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results 38
Aug 03, 2017: Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results 40
May 09, 2017: Infinity Provides Company Reports First Quarter 2017 Financial Results 43
Mar 14, 2017: Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results 44
Corporate Communications 46
Aug 07, 2018: Infinity Pharmaceuticals appoints Samuel Agresta as Chief Medical Officer 46
Mar 08, 2018: Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board 47
Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer 49
Jan 04, 2017: Infinity Announces Organizational Changes 50
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11
Bristol-Myers Squibb and Infinity Pharma Enter into Collaboration Agreement 12
Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 13
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 14
Pharm-Olam International Enters into Agreement with Infinity Pharma 15
Lead Discovery Center Partners with Infinity Pharma 16
PellePharm Enters into Licensing Agreement with Infinity Pharma 17
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 18
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 20
Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 21
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 23
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 24
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 26
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 27
Infinity Pharmaceuticals Inc, Key Competitors 29
Infinity Pharmaceuticals Inc, Key Employees 30
Infinity Pharmaceuticals Inc, Subsidiaries 31

List of Figures
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Infinity Pharmaceuticals Inc (INFI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bank of Jordan (BOJX):企業の財務・戦略的SWOT分析
    Summary Bank of Jordan is a banking service provider. The company offers corporate services, leasing services, retail services, SMEs services and securities services. It also provides car loans, mortgage, personal loans and credit cards. Bank of Jordan’s retail services include accounts and deposits …
  • Vascular Biogenics Ltd (VBLT):製薬・医療:M&Aディール及び事業提携情報
    Summary Vascular Biogenics Ltd (VBL) is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company’s product pipeline includes VB-111. VBL’s product VB-111 is an anti-angiogenic agent for the specific inhibition of tumor vascular growth for ca …
  • Euromoney Institutional Investor PLC:企業の戦略・SWOT・財務分析
    Euromoney Institutional Investor PLC - Strategy, SWOT and Corporate Finance Report Summary Euromoney Institutional Investor PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Cryogenmash:企業の戦略的SWOT分析
    Cryogenmash - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Suburban Propane Partners LP (SPH):企業の財務・戦略的SWOT分析
    Summary Suburban Propane Partners LP (Suburban Propane) distributes and markets energy-related products. The company supplies propane, fuel oil and refined fuels, and markets natural gas and electricity in deregulated markets. It also provides installation and service of various types of whole-house …
  • Sernova Corp (SVA):製品パイプライン分析
    Summary Sernova Corp (Sernova) is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company is developing Cell Pouch System, an implantable medical device, which offers a natural organ- …
  • Caribou Coffee Company Inc:企業の戦略的SWOT分析
    Caribou Coffee Company Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Synairgen Plc (SNG):製薬・医療:M&Aディール及び事業提携情報
    Summary Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG …
  • Challenge Group Holdings PTE. LTD.:企業の戦略・SWOT・財務情報
    Challenge Group Holdings PTE. LTD. - Strategy, SWOT and Corporate Finance Report Summary Challenge Group Holdings PTE. LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Cytodyn Inc (CYDY):製薬・医療:M&Aディール及び事業提携情報
    Summary Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies t for the treatment of Human Immunodeficiency Virus (HIV) infections. The company's products pipeline include PRO 140, Cytofe …
  • Camping World Holdings, Inc. (CWH):企業の財務・戦略的SWOT分析
    Camping World Holdings, Inc. (CWH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Ricardo plc:戦略・SWOT・企業財務分析
    Ricardo plc - Strategy, SWOT and Corporate Finance Report Summary Ricardo plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Advanced BioScience Laboratories Inc-製薬・医療分野:企業M&A・提携分析
    Summary Advanced BioScience Laboratories Inc (ABL), a subsidiary of Institut Merieux SA is a contract research and manufacturing company that provides services to life sciences industry. The company develops vaccines, therapeutics and other biologic products. It provides proof-of-concept in vivo stu …
  • American Bio Medica Corp (ABMC):企業の財務・戦略的SWOT分析
    Summary American Bio Medica Corp (ABMC) is a biotechnology company that develops, manufactures and markets immunoassay test kits. The company’s products include Rapid TOX, a point of collection testing product that detects 1-10 drugs of abuse in a urine specimen; Rapid One, a test cassette which is …
  • Hogan Lovells International LLP:企業の戦略的SWOT分析
    Hogan Lovells International LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Shanghai SECCO Petrochemical Co Ltd:企業の戦略的SWOT分析
    Shanghai SECCO Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Becton, Dickinson:企業の戦略・SWOT・財務情報
    Becton, Dickinson - Strategy, SWOT and Corporate Finance Report Summary Becton, Dickinson - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • bitop AG-医療機器分野:企業M&A・提携分析
    Summary Bitop AG (bitop) is a developer, manufacturer and marketer of cosmetic ingredients. The company offers extremolytes, medical devices, cosmetic ingredients and bio-stabilizer products. It offers medical devices for dermatology, allergy, cough and cold; airway diseases and dry epithelia applic …
  • KeyCorp:企業の戦略・SWOT・財務情報
    KeyCorp - Strategy, SWOT and Corporate Finance Report Summary KeyCorp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • UDG Healthcare Plc (UDG):企業の財務・戦略的SWOT分析
    UDG Healthcare Plc (UDG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆